Significantly reduces irritability
Does not disturb sleep cycles.
No weaning like other vibrations.
2nd Patent applies to infant apneic events
The US Patent and Trademark Office (USPTO) issued the 2nd patent for Prapela’s infant health-promoting technology. The new patent applies to infant apneic events which are common especially in premature newborns.
Clinical studies demonstrate SVS can enhance the rhythmicity of infant breathing and improve relaxation. In a study published in Pediatrics, the Journal of the American Academy of Pediatrics (AAP), SVS was shown to significantly reduce apneic events in preterm infants. Prapela, Inc. has exclusively licensed SVS for infant health from Harvard’s Office of Technology Development (OTD).
Prapela about to release SVS in its “next generation” baby box soon
The US Patent and Trademark Office (USPTO) issued the first patent for Prapela’s infant health-promoting technology. The first Stochastic Vibrotactile Stimulation (SVS) technology patent applies to reducing infant irritability and crying related to colic and neonatal abstinence syndrome (NAS).
Clinical studies demonstrate SVS can enhance the rhythmicity of infant breathing and improve relaxation. Doctors recommend soothing colicky babies and newborns with NAS with skin to skin contact, snuggling, swaddling and caring for them in a dark, quiet room. Prapela’s SVS is a new tool to complement these proven techniques.
Previously, Prapela’s SVS Baby Box took top honors in the “Next Gen Baby Box Quickfire Challenge” held in Helsinki, Finland sponsored by Johnson & Johnson, Janssen and the Finnish Innovation Fund.
Prapela's SVS solution for Neonatal Abstinence Syndrome awarded NIDA grant.
The grant award from the NIH/National Institute on Drug Abuse will accelerate the research and commercialization of the Prapela SVS hospital bassinet pad to treat newborns diagnosed with neonatal abstinence syndrome. SVS is a patented, non-habit forming vibration with peer-review publications reporting it improves breathing, heart rate and relaxation in newborns diagnosed with NAS. Prapela is so grateful to so many organizations that have helped the company accelerate availability of SVS including: Children’s National Health System, Johnson & Johnson, The State of Ohio and its Third Frontier Program, the Charles H. Hood Foundation, the Southwest National Pediatric Device Consortium along the FDA funded Pediatric Device Consortium program.